Table 3: Quantum Mechanics (QM) complexation Gibbs free energy (∆∆GQMcom) and its components for the training set.
Training seta | ∆∆HQMb | ∆∆Gcavc | ∆∆Geld | ∆∆Gdispe | ∆∆Grepf | ∆∆Gcompg | h |
---|---|---|---|---|---|---|---|
(kcal/mol) | (µM) | ||||||
AVSH1 | 0 | 0 | 0 | 0 | 0 | 0 | 16.5 |
AVSH2 | 1.88 | 0.59 | 6.38 | -2 | 0.23 | 2.7 | 22.4 |
AVSH3 | -0.82 | 3.81 | -6.81 | -9 | 0.88 | 3.9 | 9.22 |
AVSH4 | -0.87 | 1.87 | -5.32 | -0.19 | 0.08 | 1.1 | 4.95 |
AVSH5 | 1.49 | -0.02 | -10.89 | -6.25 | 0.43 | 1.9 | 21.6 |
AVSH6 | -8.08 | 0.85 | 4.57 | -0.67 | 0.07 | -7.2 | 0.35 |
aFor the chemical structures of the training set of inhibitors see Table 1; b∆∆HQM is the relative enthalpic contribution to the Gibbs free energy change related to Enzyme-Inhibitor (E:I) complex formation derived by Quantum Mechanics (QM): Iref is the reference inhibitor AVSH1; c∆∆GQM_solv is the relative solvation Gibbs free energy contribution to the Gibbs free energy change of E:I complex formation obtained by Polarizable Continuum Model (PCM) approach: ∆∆GQM_solv = ∆∆Gcavc+ ∆∆Geld + ∆∆Gdispe + ∆∆Grepf = [GQM_solv{E:Ix} - GQM_solv{Ix}] - [GQM_solv{E:Iref} - GQM_solv{Iref}]; g is the relative Gibbs free energy change related to E:Ix complex formation; h is the experimental half-maximal inhibitory concentration of FP2 inhibition obtained from reference [13].